Small Molecule Therapeutics

• Strykagen’s small molecules were identified using a novel α7β1 integrin muscle cell-based assay and by screening over 400,000 compounds using qHTS technology.

• Stryka-969 has been shown to increase α7β1 integrin in DMD patient muscle cells, can be orally delivered, and increases muscle strength in preclinical studies.

• Strykagen’s small molecule therapeutics should be effective in treating DMD, MDC1A and LGMD2I and be independent of the site of the gene defect.

• Stryakgen has the exclusive worldwide license to develop and market these small molecules and their derivatives for the treatment of muscular dystrophy.